Skip to main content

Table 2 Comparison of clinicopathologic features among patients with CHC, SHC, pure HCC, and pure ICC

From: Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study

Characteristic CHC (n = 34) SHC (n = 29) Pure HCC (n = 50) Pure ICC (n = 50) P valuec
  V1 V2 V3
Sex
 Men 30 (88.2) 25 (86.2) 47 (94.0) 35 (70.0) 0.810 0.383 0.051
 Women 4 (11.8) 4 (13.8) 3 (6.0) 15 (30.0)
Age (years)a 52 (24–78) 49 (24–81) 53 (26–73) 60 (42–81) 0.434 0.713 0.342
Tumor size (cm)b 4.05 ± 2.45 3.49 ± 2.11 6.26 ± 2.81 5.24 ± 3.42 0.237 0.146  
  2.96 ± 1.68    0.168   0.293
HBsAg (+) 32 (94.1) 27 (93.1) 43 (86.0) 28 (56.0) 1.000 0.301 <0.001
Liver cirrhosis 20 (58.9) 12 (41.4) 34 (86.0) 12 (24.0) 0.167 0.389 <0.001
Vascular invasion 17 (50.0) 9 (31.0) 1 (2.0) 6 (12.0) 0.128 <0.001 <0.001
Lymph node metastasis 6 (17.6) 4 (13.8) 0 (0.0) 10 (20.0) 0.741 0.003 0.787
AFP ≥20 μg/L 24 (70.6) 20 (69.0) 33 (66.0) 15 (30.0) 0.889 0.659 <0.001
CA19–9 ≥38 U/mL 14 (41.2) 27 (93.1) 2 (2.0) 22 (44.0) <0.001 <0.001 0.797
AFP ≥20 μg/L and CA19–9 ≥38 U/mL 10 (29.4) 4 (13.8) 1 (2.0) 5 (10.0) 0.137 <0.001 0.023
HCC
 Histologic type
  Coarse trabecular pattern 21 (61.8) 19 (65.5) 34 (68.0)   0.025 0.834  
  Fine trabecular pattern 3 (8.8) 8 (27.6) 4 (8.0)     
  Others 10 (29.4) 2 (6.9) 12 (24.0)     
 Edmondson grade
  I–II 4 (11.8) 11 (37.9) 9 (18.0)   0.015 0.438  
  III–IV 30 (88.2) 18 (62.1) 41 (82.0)     
ICC
 Histologic type
  Tubular pattern 29 (85.3) 28 (96.6)   46 (92.0) 0.139   0.266
  Others 5 (14.7) 1 (3.4)   4 (8.0)    
 Differentiation grade
  Moderate and well 24 (70.6) 25 (86.2)   29 (58.0) 0.137   0.241
  Poor 10 (29.4) 4 (13.8)   21 (42.0)    
Overall survival time (months)b 15.37 ± 2.04 24 ± 4.23 29.2 ± 4.1 10.1 ± 2.3 0.047 0.021 0.017
Disease-free survival time (months)b 8.85 ± 1.3 16.9 ± 3.6 22.7 ± 3.9 5.62 ± 0.7 0.038 <0.001 0.397
  1. CHC combined hepatocellular and cholangiocarcinoma, SHC separated hepatocellular carcinoma and intrahepatic cholangiocarcinoma, HCC hepatocellular carcinoma, ICC intrahepatic cholangiocarcinoma, HBsAg 15 hepatitis B surface antigen, AFP ɑ-fetoprotein, CA19-9 carbohydrate antigen 19-9, ▲ HCC, ICC
  2. aThese values are presented as median followed by range in the parentheses
  3. bThese data are presented as mean ±standard deviation; other values are presented as number of patients followed by percentage in the parentheses
  4. c P value for V1 CHC versus SHC; V2 CHC versus pure HCC; V3 CHC versus pure ICC